1. Cancer Biology

Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma

  1. Bo Gong  Is a corresponding author
  2. Ling Zhong
  3. Peng Hao
  4. Qian Zhang
  5. Tao Jiang
  6. Huan Li
  7. Jialing Xiao
  8. Chenglong Li
  9. Lan Luo
  10. Ping Shuai
  11. Liang Wang
  12. Yuping Liu
  13. Yi Shi
  14. Wei Zhang  Is a corresponding author
  1. University of Electronic Science and Technology of China, China
  2. Chengdu University of Traditional Chinese Medicine, China
https://doi.org/10.7554/eLife.75340
Share this article
Cite this article
  1. Bo Gong
  2. Ling Zhong
  3. Peng Hao
  4. Qian Zhang
  5. Tao Jiang
  6. Huan Li
  7. Jialing Xiao
  8. Chenglong Li
  9. Lan Luo
  10. Ping Shuai
  11. Liang Wang
  12. Yuping Liu
  13. Yi Shi
  14. Wei Zhang
(2022)
Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma
eLife 11:e75340.
https://doi.org/10.7554/eLife.75340
  2. Download BibTeX
  3. Download .RIS

Abstract

Multiple myeloma (MM) accounts for ~10% of all haematologic malignancies. Little is known about high intratumour heterogeneities in patients stratified by the Revised International Staging System (R-ISS). Herein, we constructed a single-cell transcriptome atlas to compare differential expression patterns among stages. We found that a novel cytotoxic plasma cell (PC) population exhibited with NKG7 positive was obviously enriched in stage II patients. Additionally, a malignant plasma cell population with significantly elevated expression of MKI67 and PCNA was associated with unfavourable prognosis and Epstein-Barr virus (EBV) infection in our collected samples. Moreover, Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) was found and verified to promote proliferation of MM cell lines, suggesting RRM2 may serve as a detrimental marker in MM. The percentages of CD8+ T cells and NKT cells decreased along with R-ISS stages, reflecting the plasticity of the tumour immune microenvironment. Importantly, their crosstalks with myeloid cells and PC identified several potential immunotargets such as SIRPA-CD47, and CD74-MIF, respectively. Collectively, this study provided an R-ISS-related single-cell MM atlas and revealed the clinical significance of novel PC clusters, as well as potential immunotargets in MM progression.

Data availability

Sequencing data have been deposited in GEO under accession code GSE176131.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Bo Gong

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    For correspondence
    gongbo2007@hotmail.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2763-6829

  2. Ling Zhong

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  3. Peng Hao

    Department of Orthopaedics, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  4. Qian Zhang

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  5. Tao Jiang

    Department of Hematology, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  6. Huan Li

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  7. Jialing Xiao

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  8. Chenglong Li

    Department of Hematology, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  9. Lan Luo

    Chengdu University of Traditional Chinese Medicine, Chengdu, China
    Competing interests
    The authors declare that no competing interests exist.

  10. Ping Shuai

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  11. Liang Wang

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  12. Yuping Liu

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  13. Yi Shi

    Department of Health Management, University of Electronic Science and Technology of China, ChengDu, China
    Competing interests
    The authors declare that no competing interests exist.

  14. Wei Zhang

    Department of Orthopaedics, University of Electronic Science and Technology of China, ChengDu, China
    For correspondence
    zhangwspine@163.com
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Natural Science Foundation of China (Youth Funds,82002212)

  • Ling Zhong

Science & Technology Department of Sichuan Province (Applied Basic Research,2022YFS0100)

  • Peng Hao

Chengdu Science and Technology Bureau (Applied Basic Research,2019-YF05-00572-SN)

  • Ling Zhong

China Postdoctoral Science Foundation (general program，2019M663567)

  • Ling Zhong

UESTC (Basic scientific research,ZYGX2020J024)

  • Ling Zhong

UESTC (Medicine-engineering interdisciplinary,ZYGX2021YGLH006)

  • Ling Zhong

Science &Technology Department of Sichuan Province (Outstanding Youth Fund，2022JDTD0024)

  • Bo Gong

Chengdu Science and Technology Bureau (Applied Basic Research,2022-YF05-01625-SN)

  • Bo Gong

Sichuan cadre health care project (Sichuan cadre health care project,2022-216)

  • Wei Zhang

UESTC (Medicine-engineering interdisciplinary,ZYGX2021YGLH204)

  • Wei Zhang

The roles of the funders were to do single cell sequence, analysis data, and verify the conclusions.

Reviewing Editor

  1. Yang Liang, Sun Yat-sen University Cancer Center, China

Ethics

Human subjects: Written informed consents were obtained from all subjects. All experimental procedures were approved by the Medical ethics committee of Sichuan Provincial People's Hospital and carried out in accordance with the principles of the Declaration of Helsinki. ALL of the patients signed the informed consent containing contact Information, the purpose of the study, risks and benefits from this study, consent to publish the manuscript. The protocol numbers was 2020-240.

Version history

  1. Received: November 7, 2021
  2. Preprint posted: December 7, 2021 (view preprint)
  3. Accepted: October 17, 2022
  4. Accepted Manuscript published: October 31, 2022 (version 1)
  5. Version of Record published: November 18, 2022 (version 2)

Copyright

© 2022, Gong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,014
    views
  • 136
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Bo Gong
  2. Ling Zhong
  3. Peng Hao
  4. Qian Zhang
  5. Tao Jiang
  6. Huan Li
  7. Jialing Xiao
  8. Chenglong Li
  9. Lan Luo
  10. Ping Shuai
  11. Liang Wang
  12. Yuping Liu
  13. Yi Shi
  14. Wei Zhang
(2022)
Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma
eLife 11:e75340.
https://doi.org/10.7554/eLife.75340

Share this article

https://doi.org/10.7554/eLife.75340

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Cell Biology

    A syngeneic spontaneous zebrafish model of tp53-deficient, EGFRvIII, and PI3KCAH1047R-driven glioblastoma reveals inhibitory roles for inflammation during tumor initiation and relapse in vivo

    Alex Weiss, Cassandra D'Amata ... Madeline N Hayes
    Research Article

    High-throughput vertebrate animal model systems for the study of patient-specific biology and new therapeutic approaches for aggressive brain tumors are currently lacking, and new approaches are urgently needed. Therefore, to build a patient-relevant in vivo model of human glioblastoma, we expressed common oncogenic variants including activated human EGFRvIII and PI3KCAH1047R under the control of the radial glial-specific promoter her4.1 in syngeneic tp53 loss-of-function mutant zebrafish. Robust tumor formation was observed prior to 45 days of life, and tumors had a gene expression signature similar to human glioblastoma of the mesenchymal subtype, with a strong inflammatory component. Within early stage tumor lesions, and in an in vivo and endogenous tumor microenvironment, we visualized infiltration of phagocytic cells, as well as internalization of tumor cells by mpeg1.1:EGFP+ microglia/macrophages, suggesting negative regulatory pressure by pro-inflammatory cell types on tumor growth at early stages of glioblastoma initiation. Furthermore, CRISPR/Cas9-mediated gene targeting of master inflammatory transcription factors irf7 or irf8 led to increased tumor formation in the primary context, while suppression of phagocyte activity led to enhanced tumor cell engraftment following transplantation into otherwise immune-competent zebrafish hosts. Altogether, we developed a genetically relevant model of aggressive human glioblastoma and harnessed the unique advantages of zebrafish including live imaging, high-throughput genetic and chemical manipulations to highlight important tumor-suppressive roles for the innate immune system on glioblastoma initiation, with important future opportunities for therapeutic discovery and optimizations.

    1. Cancer Biology
    2. Cell Biology

    Cancer: Modeling glioblastoma

    Ian Lorimer
    Insight

    Establishing a zebrafish model of a deadly type of brain tumor highlights the role of the immune system in the early stages of the disease.

    1. Cancer Biology

    YAP/TAZ enhances P-body formation to promote tumorigenesis

    Xia Shen, Xiang Peng ... Chen-Ying Liu
    Research Article

    The role of processing bodies (P-bodies) in tumorigenesis and tumor progression is not well understood. Here, we showed that the oncogenes YAP/TAZ promote P-body formation in a series of cancer cell lines. Mechanistically, both transcriptional activation of the P-body-related genes SAMD4A, AJUBA, and WTIP and transcriptional suppression of the tumor suppressor gene PNRC1 are involved in enhancing the effects of YAP/TAZ on P-body formation in colorectal cancer (CRC) cells. By reexpression of PNRC1 or knockdown of P-body core genes (DDX6, DCP1A, and LSM14A), we determined that disruption of P-bodies attenuates cell proliferation, cell migration, and tumor growth induced by overexpression of YAP5SA in CRC. Analysis of a pancancer CRISPR screen database (DepMap) revealed co-dependencies between YAP/TEAD and the P-body core genes and correlations between the mRNA levels of SAMD4A, AJUBA, WTIP, PNRC1, and YAP target genes. Our study suggests that the P-body is a new downstream effector of YAP/TAZ, which implies that reexpression of PNRC1 or disruption of P-bodies is a potential therapeutic strategy for tumors with active YAP.